share_log

Uncovering Potential: PDS Biotechnology's Earnings Preview

Uncovering Potential: PDS Biotechnology's Earnings Preview

揭示潛力:pds biotechnology 的收益預覽
Benzinga ·  11/13 11:02

PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Thursday, 2024-11-14. Here's what investors need to know before the announcement.

PDS Biotechnology(納斯達克股票代碼:PDSB)定於2024-11-14星期四發佈其最新的季度收益報告。以下是投資者在宣佈之前需要了解的內容。

Analysts estimate that PDS Biotechnology will report an earnings per share (EPS) of $-0.28.

分析師估計,PDS Biotechnology將公佈的每股收益(EPS)爲-0.28美元。

The announcement from PDS Biotechnology is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

PDS Biotechnology的宣佈備受期待,投資者正在尋求超出預期的消息以及對下一季度的有利指導。

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

對於新投資者來說,值得注意的是,指導可能是股價走勢的關鍵決定因素。

Past Earnings Performance

過去的收益表現

Last quarter the company beat EPS by $0.11, which was followed by a 0.98% drop in the share price the next day.

上個季度,該公司每股收益高出0.11美元,隨後第二天股價下跌0.98%。

Here's a look at PDS Biotechnology's past performance and the resulting price change:

以下是PDS Biotechnology過去的表現以及由此產生的價格變化:

Quarter Q2 2024 Q1 2024 Q4 2023 Q3 2023
EPS Estimate -0.34 -0.37 -0.44 -0.45
EPS Actual -0.23 -0.30 -0.35 -0.35
Price Change % -1.0% 1.0% 3.0% 1.0%
季度 2024 年第二季度 2024 年第一季度 2023 年第四季度 2023 年第三季度
每股收益估算 -0.34 -0.37 -0.44 -0.45
實際每股收益 -0.23 -0.30 -0.35 -0.35
價格變動% -1.0% 1.0% 3.0% 1.0%
bigjpg

Stock Performance

股票表現

Shares of PDS Biotechnology were trading at $2.96 as of November 12. Over the last 52-week period, shares are down 56.38%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

截至11月12日,PDS Biotechnology的股票交易價格爲2.96美元。在過去的52週中,股價下跌了56.38%。鑑於這些回報率通常爲負數,長期股東在本業績發佈時可能會看跌。

To track all earnings releases for PDS Biotechnology visit their earnings calendar on our site.

要追蹤PDS Biotechnology的所有業績,請訪問我們網站上的業績日曆。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自動化內容引擎生成,並由編輯審閱。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論